Tag: Pierre Fabre Laboratories
Pierre Fabre Laboratories and RedRidge Bio partner
Pierre Fabre Laboratories and RedRidge Bio (“RedRidge”) have announced an exclusive R&D collaboration and license agreement to identify and develop biparatopic antibody (BPA) drug...
Pierre Fabre & Scorpion Therapeutics partner in cancer treatment
Pierre Fabre Laboratories, a global player in oncology, and Scorpion Therapeutics, a clinical-stage oncology company specializing in cancer treatment by redefining the frontier of...
European Commission nod for Pierre Fabre Braftovitovi
Pierre Fabre Laboratories announced that the European Commission (EC) has approved Braftovitovi (encorafenib) in combination with Mektovi (binimetinib) for the treatment of adult patients...
Pierre Fabre Laboratories receives CHMP positive opinion for Braftovi in combination...
Pierre Fabre Laboratories announced that the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the approval of Braftovi (encorafenib)...
Potential Treatment for patients with solid tumors
Pierre Fabre Laboratories recently announced the filing of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a first-in-human (FIH) Phase I/II clinical trial with PFL-002/VERT-002 for solid tumors...